What fertility-related drug programs did Merck KGaA acquire from PostEra, and what is the reported financial scale of the deal?

Merck KGaA acquired PostEra’s two fertility programs, which focus on oral drug candidates for fertility and polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovarian syndrome. The companies declined to disclose exact financial terms, but PostEra CEO Aaron Morris stated that Merck KGaA is paying an amount in the 'mid-double-digit millions'—indicating a range roughly between $20 million and $90 million.

Why is PostEra’s shift toward fertility and PMOS drug development significant in the context of its recognition as one of C&EN’s 10 Start-Ups to Watch in 2025?

PostEra’s strategic pivot—made around a year ago—to developing oral drug candidates specifically for fertility and PMOS marked a deliberate refocusing of its pipeline toward high-need therapeutic areas with substantial unmet medical needs; this shift proved pivotal, as it directly led to Merck KGaA’s acquisition of its two fertility programs, validating the scientific and commercial promise that earned PostEra a spot on C&EN’s 10 Start-Ups to Watch in 2025 list.

Merck KGaA Buys PostEra’s Oral Fertility Molecules

Sep 9, 2026

Merck KGaA has acquired PostEra’s two oral fertility molecule programs in a deal worth mid-double-digit millions. This move capitalizes on PostEra's recent strategic shift toward developing drug candidates for fertility and metabolic ovarian syndrome.

cen

2026-06-25

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

2026-06-26

Merck to Acquire US-Based Life Sciences Firm Bio-Techne for $11.3 Billion

2026-09-09

Merck KGaA Buys PostEra’s Oral Fertility Molecules

2026-10-19

Merck KGaA Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA Buys PostEra’s Oral Fertility Molecules

FAQ